Drugs / Pfizer-BioNTech mRNA COVID-19 vaccine
Pfizer-BioNTech mRNA COVID-19 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05212610 | Mar 2022 → Mar 2025 | COVID-19 | University of Michigan | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07287137 Comparator | Nov 2025 → Sep 2027 expected | COVID-19, influenza | Henry M. Jackson Foundation for the Advancement of Military Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pfizer-BioNTech mRNA COVID-19 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05212610 ↗ |
| Modality | Messenger RNA (mRNA) | “Pfizer-BioNTech mRNA COVID-19 vaccine” NCT05212610 ↗ |